Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

NCT07415980 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Double Expressor DLBCL

Interventions

DRUG: Polatuzumab Vedotin
DRUG: Rituximab (R)
DRUG: Chidamide

Sponsor

Sun Yat-sen University